GlassScriptPhysician profile
Lisa C Alvarez
NPI 1437315959
$9,119.93
in general payments reported to CMS, 2019-2025
38 companies · $1,746 in 2025
The $1,746 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $561 · 2021: $1,063 · 2022: $1,760 · 2023: $1,784 · 2024: $1,596 · 2025: $1,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,126.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,824.99 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $770.40 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $530.06 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $360.28 | 2019-2025 | |
| Celgene Corporation | $334.77 | 2022-2024 | Zeposia |
| Genzyme Corporation | $322.69 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $228.04 | 2021-2024 | Dificid, Recarbrio, Zerbaxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.20 | 2020-2024 | Trulance, Xifaxan |
| Ardelyx, INC. | $134.18 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $133.82 | 2019-2023 | Clenpiq |
| Intercept Pharmaceuticals, INC. | $122.23 | 2022-2023 | Ocaliva |
| Qol Medical, LLC | $119.52 | 2019-2025 | Sucraid |
| Redhill Biopharma INC. | $102.65 | 2022 | |
| Phathom Pharmaceuticals, INC. | $90.33 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $81.89 | 2023-2025 | Gimoti |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $74.62 | 2022-2023 | Dupixent |
| Shionogi INC | $72.66 | 2019 | |
| Lilly USA, LLC | $63.31 | 2024-2025 | Omvoh |
| Vivus LLC | $53.85 | 2025 | Pancreaze |
| Ironwood Pharmaceuticals, INC | $50.80 | 2023 | Linzess |
| Braintree Laboratories, INC. | $50.19 | 2019 | |
| Aimmune Therapeutics, INC. | $47.79 | 2025 | Zenpep, Vowst |
| Enterra Medical, INC. | $38.09 | 2024 | |
| Madrigal Pharmaceuticals | $35.31 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $34.06 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $32.96 | 2021-2024 | Riteclip |
| Celltrion USA INC. | $31.38 | 2024 | Vegzelma |
| Endo Pharmaceuticals INC. | $28.49 | 2019 | |
| Medtronic, INC. | $24.11 | 2025 | Pillcam |
| Fresenius Kabi USA, LLC | $23.39 | 2023 | Idacio |
| Ge Healthcare | $22.23 | 2025 | |
| Novo Nordisk INC | $19.82 | 2025 | Wegovy |
| Ethicon US, LLC | $19.14 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.51 | 2022 | |
| Perspectum Diagnostics LTD | $18.20 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.53 | 2025 | Iqirvo |
| Olympus America INC. | $15.44 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,435.34 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.